Monument Capital Management Increases Position in Eli Lilly and Company (NYSE:LLY)

Monument Capital Management lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,878 shares of the company’s stock after acquiring an additional 78 shares during the quarter. Monument Capital Management’s holdings in Eli Lilly and Company were worth $1,677,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth about $26,000. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the third quarter worth about $27,000. Legacy Financial Group LLC acquired a new position in Eli Lilly and Company during the third quarter worth about $35,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company during the third quarter worth about $36,000. Finally, Family CFO Inc acquired a new position in Eli Lilly and Company during the third quarter worth about $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Barclays upped their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a report on Monday, April 15th. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, Bank of America upped their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Trading Up 1.4 %

NYSE:LLY traded up $10.45 during trading hours on Monday, reaching $736.76. 1,221,183 shares of the company were exchanged, compared to its average volume of 3,048,823. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm has a market cap of $700.04 billion, a price-to-earnings ratio of 125.45, a PEG ratio of 1.58 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $370.68 and a 52-week high of $800.78. The stock has a 50 day simple moving average of $763.96 and a 200 day simple moving average of $661.44.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.09 earnings per share. As a group, analysts predict that Eli Lilly and Company will post 12.52 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.